4//SEC Filing
Hatzis-Schoch Brent 4
Accession 0000899243-21-006454
CIK 0001701541other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 9:24 PM ET
Size
11.4 KB
Accession
0000899243-21-006454
Insider Transaction Report
Form 4
Hatzis-Schoch Brent
SEE REMARKS
Transactions
- Exercise/Conversion
Common Stock
2021-02-12$3.20/sh+4,078$13,050→ 12,478 total - Sale
Common Stock
2021-02-12$27.19/sh−3,771$102,533→ 8,707 total - Sale
Common Stock
2021-02-12$27.66/sh−307$8,492→ 8,400 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-12−4,078→ 172,708 totalExercise: $3.20Exp: 2029-06-11→ Common Stock (4,078 underlying)
Footnotes (4)
- [F1]Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.525 to $28.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Black Diamond Therapeutics, Inc.
CIK 0001701541
Entity typeother
Related Parties
1- filerCIK 0001637054
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 9:24 PM ET
- Size
- 11.4 KB